Tag: 30-month stay
Arlyn Ackerman
30-Month Stay: How Litigation Delays Generic Drug Approval
The 30-month stay under the Hatch-Waxman Act delays generic drug approval by tying it to patent litigation. While meant to balance innovation and access, it often extends monopolies, raising drug costs and slowing patient access.
Continue Reading